3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
How expensive is the stock market right now? The S&P 500 Shiller CAPE ratio is near its second-highest level ever.
5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right
Nearly one year ago, I made four predictions about the stock market in 2024. I thought the S&P 500 would generate positive returns but lower than in 2023.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
US FDA lifts partial clinical hold on BioNTech cancer drug study
BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a...
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and ot...
2 No-Brainer Stocks to Buy Before the End of 2024
I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion.
5 Top Stocks to Buy in December
The end of the year can spur myriad feelings when deciding which stocks are the best buys.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on...
BioNTech to Acquire Biotheus to Boost Oncology Strategy
MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of...
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.
BioNTech surprises with Q3 profit driven by strong vaccine sales
BioNTech SE reported a surprising profit for the third quarter, achieving earnings of €0.81 ($0.88) per diluted share, far exceeding analyst expectations of a loss of €1.84. The Mainz, Germany-base...
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET)
BioNTech to Host Innovation Series R&D Day on November 14, 2024
MAINZ, Germany, October 31 , 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern...
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
Related Companies